1921
Volume 85, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Third generation cephalosporins are commonly used in the treatment of leptospirosis. The efficacy of first generation cephalosporins has been less well-studied. Susceptibility testing of 13 strains (11 serovars) to cefazolin and cephalexin was conducted using broth microdilution. Median minimal inhibitory concentration (MIC) for cefazolin and cephalexin ranged from < 0.016 to 2 μg/mL (MIC = 0.5 μg/mL) and from 1 to 8 μg/mL (MIC = 8 μg/mL), respectively. Efficacy of cefazolin and cephalexin in an acute lethal hamster model of leptospirosis was studied. Survival rates for cefazolin were 80%, 100%, and 100%, and survival rates for cephalexin were 50%, 80%, and 100% (treated with 5, 25, and 50 mg/kg per day for 5 days, respectively). Each treatment group showed improved survival compared with no treatment ( < 0.01), and none of the therapies, regardless of dose, was statistically significantly different than doxycycline. These results support a potential role for first generation cephalosporins as alternative therapies for leptospirosis.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2011.11-0352
2011-11-01
2020-08-12
Loading full text...

Full text loading...

/deliver/fulltext/14761645/85/5/905.html?itemId=/content/journals/10.4269/ajtmh.2011.11-0352&mimeType=html&fmt=ahah

References

  1. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM, 2003. Leptospirosis: a zoonotic disease of global. Lancet Infect Dis 3: 757771.[Crossref]
    [Google Scholar]
  2. Meites E, Jay MT, Deresinski S, Shieh WJ, Zaki SR, Tompkins L, Smith DS, 2004. Reemerging leptospirosis, California. Emerg Infect Dis 10: 406412.[Crossref]
    [Google Scholar]
  3. Tangkanakul W, Tharmaphornpil P, Plikaytis BD, Bragg S, Poonsuksombat D, Choomkasien P, Kingnate D, Ashford DA, 2000. Risk factors associated with leptospirosis in northeastern Thailand. Am J Trop Med Hyg 63: 204208.
    [Google Scholar]
  4. Vijayachari P, Sugunan AP, Shriram AN, 2008. Leptospirosis: an emerging global public health problem. J Biosci 33: 557569.[Crossref]
    [Google Scholar]
  5. Griffith ME, Hospenthal DR, Murray CK, 2006. Antimicrobial therapy of leptospirosis. Curr Opin Infect Dis 19: 533537.[Crossref]
    [Google Scholar]
  6. World Health Organization, 2003. Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control. Geneva, Switzerland: World Health Organization.
    [Google Scholar]
  7. Panaphut T, Domrongkitchaiporn S, Vibhagool A, Thinkamrop B, Susaengrat W, 2003. Ceftriaxone compared with sodium penicillin G for treatment of severe leptospirosis. Clin Infect Dis 36: 15071513.[Crossref]
    [Google Scholar]
  8. Phimda K, Hoontrakul S, Suttinont C, Chareonwat S, Losuwanaluk K, Chueasuwanchai S, Chierakul W, Suwancharoen D, Silpasakorn S, Saisongkorh W, Peacock SJ, Day NP, Suputtamongkol Y, 2007. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 51: 32593263.[Crossref]
    [Google Scholar]
  9. Suputtamongkol Y, Niwattayakul K, Suttinont C, Losuwanaluk K, Limpaiboon R, Chierakul W, Wuthiekanun V, Triengrim S, Chenchittikul M, White NJ, 2004. An open, randomized controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis 39: 14171424.[Crossref]
    [Google Scholar]
  10. Yoshimori RN, Goldberg HS, Blenden DC, 1965. Cephalothin in the treatment of experimental leptospirosis in hamsters. Antimicrob Agents Chemother 5: 450452.
    [Google Scholar]
  11. Alexander AD, Rule PL, 1986. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob Agents Chemother 30: 835839.[Crossref]
    [Google Scholar]
  12. Murray CK, Hospenthal DR, 2004. Broth microdilution susceptibility testing for Leptospira spp. Antimicrob Agents Chemother 48: 15481552.[Crossref]
    [Google Scholar]
  13. Murray CK, Hospenthal DR, 2004. Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by broth microdilution technique. Antimicrob Agents Chemother 48: 40024005.[Crossref]
    [Google Scholar]
  14. Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK, 2008. Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira . Antimicrob Agents Chemother 52: 27502754.[Crossref]
    [Google Scholar]
  15. Griffith ME, Moon JE, Johnson EN, Clark KP, Hawley JS, Hospenthal DR, Murray CK, 2007. Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model. Antimicrob Agents Chemother 51: 26152617.[Crossref]
    [Google Scholar]
  16. Moon JE, Ellis MW, Griffith ME, Hawley JS, Rivard RG, McCall S, Hospenthal DR, Murray CK, 2006. Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. Antimicrob Agents Chemother 50: 19891992.[Crossref]
    [Google Scholar]
  17. Moon JE, Rivard RG, Griffith ME, Ressner RA, McCall S, Reitstetter RE, Hospenthal DR, Murray CK, 2007. Effect of timing and duration of azithromycin therapy of leptospirosis in a hamster model. J Antimicrob Chemother 59: 148151.[Crossref]
    [Google Scholar]
  18. Alt DP, Bolin CA, 1996. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am J Vet Res 57: 5962.
    [Google Scholar]
  19. Alt DP, Zuerner RL, Bolin CA, 2001. Evaluation of antibiotics for treatment of cattle infected with Leptospira borgpetersenii serovar hardjo. J Am Vet Med Assoc 219: 636639.[Crossref]
    [Google Scholar]
  20. Kirby WMM, Regamey C, 1973. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 128: S341S345.[Crossref]
    [Google Scholar]
  21. Clinical and Laboratory Standards Institute, 2008. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI Document M100-S18. Wayne, PA: Clinical and Laboratory Standards Institute.
    [Google Scholar]
  22. Levison ME, Johnson WD, Thornhill TS, Kaye D, 1969. Clinical and in vitro evaluation of cephalexin. JAMA 209: 13311336.[Crossref]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2011.11-0352
Loading
/content/journals/10.4269/ajtmh.2011.11-0352
Loading

Data & Media loading...

  • Received : 03 Jun 2011
  • Accepted : 24 Jun 2011
  • Published online : 01 Nov 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error